| Budget Amount *help |
¥229,710,000 (Direct Cost: ¥176,700,000、Indirect Cost: ¥53,010,000)
Fiscal Year 2022: ¥48,100,000 (Direct Cost: ¥37,000,000、Indirect Cost: ¥11,100,000)
Fiscal Year 2021: ¥48,100,000 (Direct Cost: ¥37,000,000、Indirect Cost: ¥11,100,000)
Fiscal Year 2020: ¥48,100,000 (Direct Cost: ¥37,000,000、Indirect Cost: ¥11,100,000)
Fiscal Year 2019: ¥48,100,000 (Direct Cost: ¥37,000,000、Indirect Cost: ¥11,100,000)
Fiscal Year 2018: ¥37,310,000 (Direct Cost: ¥28,700,000、Indirect Cost: ¥8,610,000)
|
|---|
| Outline of Final Research Achievements |
We developed various PROTAC compounds that degrade proteins with a causative role on cancer, neurodegenerative and other diseases. We also developed new technologies that induce protein degradation, including PROTACs containing peptides and decoy oligo-nucleotides as target ligands, BCR-ABL degradation by inhibition of de-ubiquitylase USP25 and mitophagy induction triggered by PROTAC-mediated ubiquitylation of mitochondrial proteins. In addition, we identified several neo-substrate proteins that are degraded by thalidomide and pomalidomide, and demonstrated their role on teratogenicity and anti-myeloma activity of these drugs.
|
